UBS analyst Matthew Weston maintained a Buy rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF111.00.Invest ...

Moves by the incoming Trump Administration may be a boon to drugmakers, Novartis AG Chief Executive Officer Vas Narasimhan ...

Ameritas Advisory Services LLC lowered its position in shares of Novartis AG (NYSE:NVS – Free Report) by 2.7% during the 4th ...

Koshinski Asset Management Inc. boosted its holdings in Novartis AG (NYSE:NVS – Free Report) by 6.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission ...

Novartis AG (NOVN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from ...

Germany’s ITM, a stalwart in the highly specialized field of radiopharmaceuticals, will soon announce the results from its ...

Welcome to the Novartis presentation at the 43rd JPMorgan Healthcare Conference. I'm Richard Vosser, European pharma analyst with JPMorgan. It's my great pleasure to introduce Vas Narasimhan, the CEO ...

Plaque Psoriasis BURLINGAME, CA, UNITED STATES, January 27, 2025 /EINPresswire / -- The worldwide Plaque Psoriasis <a target=_blank href=h ...

The Anti-Corruption Commission (ACC), during the hearing, informed the court that the anti-graft body is investigating the ...

The roller-coaster ride for Novartis—as it uses every bit of its legal muscle to extend Entresto's market exclusivity—took ...

An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.